By David Wild
Tissue plasminogen activator (tPA) is as safe in treating ischemic stroke in patients who have sickle cell disease (SCD) as it is in those who do not have the disease, new research has shown (Stroke 2017;48[3]:686-691).
The results should reassure some clinicians who have been reluctant to administer thrombolytic therapy in this subpopulation of patients.